HCP
PACB icon

Hexagon Capital Partners’s Pacific Biosciences PACB Stock Holding History

Hexagon Capital Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,000
Closed -$13K – 1396
2022
Q2 		$13K Buy
+3,000
New +$18.2K ﹤0.01% 614

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hexagon Capital Partners's PACB Position: Q3 2022 in Review

Hexagon Capital Partners sold out of Pacific Biosciences (PACB) in Q3 2022, closing a stake of 3,000 shares — an estimated $13K sold.

Hexagon Capital Partners first reported a position in PACB in Q2 2022 and held it in 1 quarter. The position peaked at $13K in Q2 2022. 227 funds tracked by Wall St. Rank hold PACB as of Q3 2022.

  • Hexagon Capital Partners reported no remaining Pacific Biosciences position as of Q3 2022 after selling out during the quarter.
  • Hexagon Capital Partners sold 3,000 Pacific Biosciences shares in Q3 2022, an estimated $13K.
  • Hexagon Capital Partners first reported a position in Pacific Biosciences in Q2 2022 and held it in 1 quarter.
  • Hexagon Capital Partners's Pacific Biosciences position peaked at $13K in Q2 2022.
  • 227 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2022.

Based on Hexagon Capital Partners's 13F filing for Q3 2022, filed 17 Oct 2022.